Items Tagged ‘CB-839’

June 19th, 2017

FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma

By

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with afinitor® (everolimus), for the treatment of patients with metastatic renal cell carcinoma who have received 2 or more prior lines of therapy.  CB-839 is a first-in-class, oral, selective, potent inhibitor of glutaminase being evaluated in Phase 1/2 clinical […]

View full entry

Tags: afinitor, Calithera Bioscience, CB-839, everolimus, kidney cancer, News, precision medicine, Renal Cancer, renal cell carcinoma